Researchers to Develop Vaccines, Therapies for Nipah and Hendra Viruses

The Uniformed Services University of the Health Sciences (USU), along with Profectus Biosciences, Inc., the Vanderbilt University Medical Center, Mapp Biopharmaceutical, Inc., and the University of Texas Medical Branch (UTMB), have been awarded up to $24.5 million to advance treatments for the highly lethal henipaviruses, Nipah and Hendra.

Infections among Contacts of Patients with Nipah Virus, India

Researchers conducted a serosurvey of 155 healthcare workers and 124 household and community members who had close contact with 18 patients who had laboratory-confirmed Nipah virus infections in Kerala, India. They detected three subclinical infections; two persons had IgM and IgG and 1 only IgM against Nipah virus.

Ebola vaccine technology could speed up development of other vaccines

In addition to an Ebola vaccine, the Coalition for Epidemic Preparedness Innovations is currently funding the development of vaccines for Lassa fever, Middle East respiratory syndrome, Nipah virus, and coronavirus at the Jenner Institute; and by using the same technology as the Ebola vaccine — called viral vectors — researchers can significantly reduce the time it takes to develop vaccines.

CEPI Awards Contract Worth Up To $19 million to Oxford University and Janssen Vaccines to Develop MERS, Lassa, and Nipah Vaccines

The Coalition for Epidemic Preparedness Innovations (CEPI) has announced a collaboration to advance the development and manufacture of a vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) along with preclinical development of novel vaccines against Lassa and Nipah viruses.